Institutional Fund
Venbio Partners LLC
San Francisco, CACIK 17763825 filings on record
Portfolio Value
$280.55M
Q1 2026
Holdings
6
Reported positions
New Buys
0
Opened this quarter
QoQ Change
+29.7%
from $216.27M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Pharvaris N V46.7%
- Alumis Inc35.6%
- Alx Oncology Hldgs Inc9.2%
- Harmony Biosciences Hldgs In4.9%
- Lyell Immunopharma Inc2.4%
- Artiva Biotherapeutics Inc1.2%
Portfolio Holdings
6 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Pharvaris N V | 4.64M | $131.06M | 46.7% | 0 | Held |
| 2 | Alumis Inc | 4.53M | $99.76M | 35.6% | −91.4K | Reduced |
| 3 | Alx Oncology Hldgs Inc | 12.88M | $25.83M | 9.2% | +3.18M | Added |
| 4 | Harmony Biosciences Hldgs In | 489.2K | $13.70M | 4.9% | 0 | Held |
| 5 | Lyell Immunopharma Inc | 337.7K | $6.77M | 2.4% | 0 | Held |
| 6 | Artiva Biotherapeutics Inc | 531.3K | $3.42M | 1.2% | −117.2K | Reduced |